Skip to main content
Erschienen in: Langenbeck's Archives of Surgery 5/2005

01.09.2005 | Original Article

Palliative management strategies of advanced gastrointestinal carcinoid neoplasms

verfasst von: Paola Sartori, Chiara Mussi, Carlo Angelini, Stefano Crippa, Roberto Caprotti, Franco Uggeri

Erschienen in: Langenbeck's Archives of Surgery | Ausgabe 5/2005

Einloggen, um Zugang zu erhalten

Abstract

Background/aims

Optimal management of gastrointestinal carcinoid neoplasms that metastasize to the liver is controversial. Although operative resection seems to be the most effective approach to metastatic disease, hepatic metastases are usually multicentric and often non-resectable. We investigated the effectiveness of several forms of palliative tumor cytoreduction followed by administration of somatostatin analogues in advanced carcinoid neoplasms.

Methods

We reviewed our experience with 34 patients with gastrointestinal carcinoid neoplasms. Eighteen patients had metastases and 14 had hormonal symptoms. Twenty-two patients underwent radical surgery, ten with multiple liver metastases were treated with a combination of debulking (resection, radiofrequency ablation, chemoembolization), followed by medical treatment with long-acting octreotide and eventually by radiolabelled somatostatin analogues, and two patients with intractable disease received only biotherapies.

Results

The six patients with metastatic disease who underwent radical curative liver resection had a median survival of 52 months, compared with a median survival of 48 months in the ten patients who underwent palliative debulking. Symptomatic improvement was observed in all the patients after debulking procedures. The two patients who underwent only medical treatment died after 9 and 18 months.

Conclusions

Aggressive tumor debulking should be performed in patients with liver metastases already at diagnosis even when complete resection is not feasible because the combination of cytoreductive procedures followed by biotherapies may provide good long-term survival and achieves symptom control in most patients with advanced disease.
Literatur
1.
Zurück zum Zitat Bax NSD, Woods HF, Batchelor A, Jennings M (1996) Clinical manifestations of carcinoid disease. World J Surg 20(2):142–146CrossRefPubMed Bax NSD, Woods HF, Batchelor A, Jennings M (1996) Clinical manifestations of carcinoid disease. World J Surg 20(2):142–146CrossRefPubMed
2.
Zurück zum Zitat McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg 81:1007–1009PubMed McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in patients with gastrointestinal carcinoid tumors. Br J Surg 81:1007–1009PubMed
3.
Zurück zum Zitat Norton JA, Warren RS, Kelly MG, Zuraek B, Jensen RT (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057–1065CrossRefPubMed Norton JA, Warren RS, Kelly MG, Zuraek B, Jensen RT (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134:1057–1065CrossRefPubMed
4.
Zurück zum Zitat Nave H, Mossinger E, Feist H, Lang H, Raab H-R (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors : a retrospective, unicentric study over 13 years. Surgery 129:170–175CrossRefPubMed Nave H, Mossinger E, Feist H, Lang H, Raab H-R (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors : a retrospective, unicentric study over 13 years. Surgery 129:170–175CrossRefPubMed
5.
Zurück zum Zitat Que FG, Sarmiento JM, Nagorney DM (2002) Hepatic surgery for metastatic gastrointestinal endocrine tumors. Cancer Control 9(1):67–79PubMed Que FG, Sarmiento JM, Nagorney DM (2002) Hepatic surgery for metastatic gastrointestinal endocrine tumors. Cancer Control 9(1):67–79PubMed
6.
Zurück zum Zitat Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37CrossRefPubMed Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197:29–37CrossRefPubMed
7.
Zurück zum Zitat O’ Toole D, Maire F, Ruszniewki P (2003) Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 10:463–468CrossRefPubMed O’ Toole D, Maire F, Ruszniewki P (2003) Ablative therapies for liver metastases of digestive endocrine tumours. Endocr Relat Cancer 10:463–468CrossRefPubMed
8.
Zurück zum Zitat Schell SR, Ramsay Camp E, Caridi JG (2002) Hepatic artery embolization for control of symptoms, octreotide requirements and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670CrossRefPubMed Schell SR, Ramsay Camp E, Caridi JG (2002) Hepatic artery embolization for control of symptoms, octreotide requirements and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670CrossRefPubMed
9.
Zurück zum Zitat Hellmann P, Ladjevardi S, Skogseid B, Akestrom G, Elvin A (2002) Radio-frequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056CrossRefPubMed Hellmann P, Ladjevardi S, Skogseid B, Akestrom G, Elvin A (2002) Radio-frequency tissue ablation using cooled tip for liver metastases of endocrine tumors. World J Surg 26:1052–1056CrossRefPubMed
10.
Zurück zum Zitat Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F (2001) Receptor-mediated radiotherapy with 90 Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 28(4):426–434 Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, Bartolomei M, Orsi F, De Cicco C, Macke HR, Chinol M, de Braud F (2001) Receptor-mediated radiotherapy with 90 Y-DOTA-d-Phe1-Tyr3-octreotide. Eur J Nucl Med 28(4):426–434
11.
Zurück zum Zitat Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G (1995) Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 425(6):547–560PubMed Capella C, Heitz PU, Hofler H, Solcia E, Kloppel G (1995) Revised classification of neuroendocrine tumors of the lung, pancreas and gut. Virchows Arch 425(6):547–560PubMed
12.
Zurück zum Zitat Solcia E, Kloppel G, Sobin L (2000) Histological typing of endocrine tumors. In: WHO international histological classification of tumors, 2nd edn. Springer, Berlin Heidelberg New York, pp 56–74 Solcia E, Kloppel G, Sobin L (2000) Histological typing of endocrine tumors. In: WHO international histological classification of tumors, 2nd edn. Springer, Berlin Heidelberg New York, pp 56–74
13.
Zurück zum Zitat Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with aminoacidic infusion: a phase 1 study. Eur J Nucl Med 30:207–216 Bodei L, Cremonesi M, Zoboli S, Grana C, Bartolomei M, Rocca P, Caracciolo M, Macke HR, Chinol M, Paganelli G (2003) Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with aminoacidic infusion: a phase 1 study. Eur J Nucl Med 30:207–216
14.
Zurück zum Zitat Solcia E, Fiocca R, Rindi G, Villani L, Cornaggia M, Capella C (1993) The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 22:795–821PubMed Solcia E, Fiocca R, Rindi G, Villani L, Cornaggia M, Capella C (1993) The pathology of the gastrointestinal endocrine system. Endocrinol Metab Clin North Am 22:795–821PubMed
15.
Zurück zum Zitat Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y (1996) Metastatic endocrine tumors: medical treatment, surgical resection or liver transplantation. World J Surg 20:908–915CrossRefPubMed Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y (1996) Metastatic endocrine tumors: medical treatment, surgical resection or liver transplantation. World J Surg 20:908–915CrossRefPubMed
16.
Zurück zum Zitat Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68(2–3):94–101CrossRefPubMed Kress O, Wagner HJ, Wied M, Klose KJ, Arnold R, Alfke H (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors—a retrospective single-center analysis. Digestion 68(2–3):94–101CrossRefPubMed
17.
Zurück zum Zitat Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9(4):261–267PubMed Gupta S, Yao JC, Ahrar K, Wallace MJ, Morello FA, Madoff DC, Murthy R, Hicks ME, Ajani JA (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9(4):261–267PubMed
18.
Zurück zum Zitat Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M, Duceux M (2003) Trans-catheter chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140PubMed Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, Lasser P, Schlumberger M, Duceux M (2003) Trans-catheter chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140PubMed
19.
Zurück zum Zitat Berber E, Siperstein AE (2003) Laparoscopic radio-frequency ablation of neuroendocrine liver metastases. Probl Gen Surg 20(3):134–142CrossRef Berber E, Siperstein AE (2003) Laparoscopic radio-frequency ablation of neuroendocrine liver metastases. Probl Gen Surg 20(3):134–142CrossRef
20.
Zurück zum Zitat Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K (1997) Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogues. Acta Oncol 36:607–614PubMed Imam H, Eriksson B, Lukinius A, Janson ET, Lindgren PG, Wilander E, Oberg K (1997) Induction of apoptosis in neuroendocrine tumors of the digestive system during treatment with somatostatin analogues. Acta Oncol 36:607–614PubMed
21.
Zurück zum Zitat Sharma H, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688–1696CrossRefPubMed Sharma H, Patel YC, Srikant CB (1996) Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol Endocrinol 10:1688–1696CrossRefPubMed
22.
Zurück zum Zitat Leong WL, Pasieka JL (2002) Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and review of the literature. J Surg Oncol 79:180–187CrossRefPubMed Leong WL, Pasieka JL (2002) Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and review of the literature. J Surg Oncol 79:180–187CrossRefPubMed
23.
Zurück zum Zitat Wilander E, Bengtsson A, Norheim I, Oberg K (1986) Interferon induced nuclear DNA alteration in malignant carcinoid tumours in vivo. J Natl Cancer Inst 76:429–433PubMed Wilander E, Bengtsson A, Norheim I, Oberg K (1986) Interferon induced nuclear DNA alteration in malignant carcinoid tumours in vivo. J Natl Cancer Inst 76:429–433PubMed
24.
Zurück zum Zitat Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K (1990) Effects of interferons on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 50:3413PubMed Andersson T, Wilander E, Eriksson B, Lindgren PG, Oberg K (1990) Effects of interferons on tumor tissue content in liver metastases of carcinoid tumors. Cancer Res 50:3413PubMed
25.
Zurück zum Zitat Oberg K, Eriksson B, Janson ET (1994) The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann N Y Acad Sci 733:471–478 Oberg K, Eriksson B, Janson ET (1994) The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors. Ann N Y Acad Sci 733:471–478
26.
Zurück zum Zitat Tiensuu-Janson EM, Ahlstrom H, Andersson T, Oberg K (1992) Octreotide and interferon-alpha: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28:1647–1650CrossRef Tiensuu-Janson EM, Ahlstrom H, Andersson T, Oberg K (1992) Octreotide and interferon-alpha: a new combination for the treatment of malignant carcinoid tumours. Eur J Cancer 28:1647–1650CrossRef
27.
Zurück zum Zitat Janson ET, Oberg K (1993) Long-term management of carcinoid syndrome. Treatment with octreotide alone and in combination with alpha interferon. Acta Oncol 32:225–229 Janson ET, Oberg K (1993) Long-term management of carcinoid syndrome. Treatment with octreotide alone and in combination with alpha interferon. Acta Oncol 32:225–229
28.
Zurück zum Zitat Nold R, Frank K, Kajdan U, Trost U, Klose KJ, Arnold R (1994) Combined treatment of metastatic endocrine tumors of gastrointestinal tract with octreotide and interferon-alpha. Z Gastroenterol 32:193–197 Nold R, Frank K, Kajdan U, Trost U, Klose KJ, Arnold R (1994) Combined treatment of metastatic endocrine tumors of gastrointestinal tract with octreotide and interferon-alpha. Z Gastroenterol 32:193–197
29.
Zurück zum Zitat Kaidan U, Frank K, Elhenz K, Arnold R (1995) Effect of alpha-interferon plus octreotide on metastasized gastrointestinal endocrine tumours. Gut 37(2):A255–A256. Abstract 2283 Kaidan U, Frank K, Elhenz K, Arnold R (1995) Effect of alpha-interferon plus octreotide on metastasized gastrointestinal endocrine tumours. Gut 37(2):A255–A256. Abstract 2283
30.
Zurück zum Zitat Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130:954–962CrossRefPubMed Chung MH, Pisegna J, Spirt M, Giuliano AE, Ye W, Ramming KP, Bilchik AJ (2001) Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver. Surgery 130:954–962CrossRefPubMed
31.
Zurück zum Zitat Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine (131I-mIBG). Clin Endocrinol 55:47–60CrossRef Mukherjee JJ, Kaltsas GA, Islam N, Plowman PN, Foley R, Hikmat J, Britton KE, Jenkins PJ, Chew SL, Monson JP, Besser GM, Grossman AB (2001) Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with 131I-meta-iodobenzylguanidine (131I-mIBG). Clin Endocrinol 55:47–60CrossRef
32.
Zurück zum Zitat Hoefnagel CA (1994) Meta-iodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 21:561–581PubMed Hoefnagel CA (1994) Meta-iodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours. Eur J Nucl Med 21:561–581PubMed
33.
Zurück zum Zitat Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH (1996) Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumours. J Clin Oncol 14:1829–1838PubMed Taal BG, Hoefnagel CA, Valdes Olmos RA, Boot H, Beijnen JH (1996) Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumours. J Clin Oncol 14:1829–1838PubMed
Metadaten
Titel
Palliative management strategies of advanced gastrointestinal carcinoid neoplasms
verfasst von
Paola Sartori
Chiara Mussi
Carlo Angelini
Stefano Crippa
Roberto Caprotti
Franco Uggeri
Publikationsdatum
01.09.2005
Erschienen in
Langenbeck's Archives of Surgery / Ausgabe 5/2005
Print ISSN: 1435-2443
Elektronische ISSN: 1435-2451
DOI
https://doi.org/10.1007/s00423-005-0559-2

Weitere Artikel der Ausgabe 5/2005

Langenbeck's Archives of Surgery 5/2005 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.